Treatment of infections caused by ampicillin-resistant pathogens with a combination of ampicillin and CP-45,899.
Eleven patients infected with ampicillin-resistant organisms were treated with a combination of CP-45,899, a beta-lactamase inhibitor, and ampicillin. All infections were controlled within 7 days without any signs of toxicity.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000667:Ampicillin / Q000494:pharmacology / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010397:Penicillanic Acid / Q000627:therapeutic use*; D010403:Penicillin Resistance; D013407:Sulbactam; D065093:beta-Lactamase Inhibitors
D065093:beta-Lactamase Inhibitors; D000667:Ampicillin; D010397:Penicillanic Acid; D013407:Sulbactam